StockGlow

Editas Medicine, Inc. (8EM.F)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

2.32+0.04%Healthcare
Compare 8EM.F with
StockGlow Score
49
Neutral
BearishBullish
1 year ago+10.6%

The outlook

Editas Medicine, Inc. currently reads as neutral based on mixed vs its moving averages, 39% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.

What’s behind the score

Price trendMixed vs its moving averages
52-week range39% of the way from its 52-week low to high
Market cap
$356.0M
52-wk high
3.82
52-wk low
1.38
50-day avg
2.53
200-day avg
2.20
Trailing P/E
—

Similar stocks

38I.FIntellia Therapeutics, Inc.$9.30+1.53%ILU.FIllumina, Inc.$175.08+3.70%AB3A.FSarepta Therapeutics, Inc.$13.62+0.89%2PP.FPayPal Holdings, Inc.$49.71+0.15%FOO.FSalesforce, Inc.$155.02-0.37%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy